Our meta-analysis showed consistent prognostic efficiency of sPD-L1 in both OS and PFS, indicating that sPD-L1 could be used to monitor long-term survival outcomes in DLBCL. Here, SPDL1 is linked to diffuse large B-cell lymphoma.